Showing results (1-10 of 71) with videos related to
Sort By:
Pageof 8
Biochemical Society Transactions|October 31, 2015
Providing a molecular mechanism for P-glycoprotein; why would I bother?Richard CallaghanCancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
UCP2 - Taking the heat out of P-glycoprotein?Richard Callaghan, Mary BoardEssays in Biochemistry|March 5, 2017
The "pushmi-pullyu" of resistance to chloroquine in malariaRuth Skrzypek, Richard CallaghanEuropean Journal of Pharmacology|September 16, 2017
Dual effects of the PI3K inhibitor ZSTK474 on multidrug efflux pumps in resistant cancer cellsDivya Muthiah, Richard CallaghanThe FEBS Journal|December 8, 2009
Multidrug efflux pumps: drug binding--gates or cavity?Emily Crowley, Richard CallaghanPharmacology|February 9, 2008
Resistance to chemotherapy in cancer: a complex and integrated cellular responseHoward R Mellor, Richard CallaghanThe FEBS Journal|May 11, 2011
The lipid translocase, ABCA4: seeing is believingNaomi Laura Pollock, Richard CallaghanCancer Chemotherapy and Pharmacology|March 15, 2011
Accumulation and distribution of doxorubicin in tumour spheroids: the influence of acidity and expression of P-glycoproteinHoward R Mellor, Richard CallaghanPharmacology & Therapeutics|January 9, 2007
How can we best use structural information on P-glycoprotein to design inhibitors?Christopher A McDevitt, Richard CallaghanJournal of Lipid Research|July 20, 2004
P-glycoprotein retains function when reconstituted into a sphingolipid- and cholesterol-rich environmentSzabolcs Modok, Catherine Heyward, Richard CallaghanPageof 8